6 May

Biden backs covid-19 IP waiver in historic US policy shift

The President’s watershed decision suggests a possible shift in the country’s approach to pharma IP rights and raises tough questions about an IP suspension’s ability to help scale up vaccine production efforts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth